Workflow
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
GlobeNewswire· 2025-05-30 21:21
Core Viewpoint - Perspective Therapeutics, Inc. announced updated interim results from its ongoing Phase 1/2a clinical trial of [Pb]VMT-α-NET, presented at the 2025 ASCO Annual Meeting, indicating a favorable safety profile and promising anti-tumor activity in patients with neuroendocrine tumors [1][5][11]. Clinical Trial Overview - The Phase 1/2a clinical trial is a multi-center, open-label study focusing on patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors who have not received prior radiopharmaceutical therapy [2][12]. - Cohort 2 was reopened for enrollment in August 2024, with a total of 33 additional patients enrolled by April 30, 2025 [4][12]. Efficacy and Safety Data - Updated interim efficacy data were presented for two patients in Cohort 1 and seven patients in Cohort 2, with a data cut-off date of April 30, 2025 [3][5]. - Among 42 patients who received at least one treatment, there were no dose-limiting toxicities (DLTs) or treatment discontinuations due to adverse events reported [4][5]. - Ten patients experienced at least one Grade 3 treatment emergent adverse event (TEAE), with the majority deemed unrelated to [Pb]VMT-α-NET [4][5]. Anti-Tumor Activity - Four of seven patients in Cohort 2 experienced investigator-assessed objective responses, with three confirmed responses [5][11]. - Seven out of nine patients in Cohorts 1 and 2 remained free from disease progression after more than one year of follow-up [5][11]. Future Plans and Regulatory Engagement - The company plans to submit longer safety follow-up data and preliminary efficacy data for a subgroup for presentation at a scientific congress in the second half of 2025 [11][12]. - The company is engaging with the FDA to continue pursuing dose finding for [Pb]VMT-α-NET [10][11]. Company Background - Perspective Therapeutics, Inc. specializes in developing advanced radiopharmaceutical treatments for cancers, utilizing proprietary technology to deliver targeted radiation to cancer cells [14][15]. - The company is also developing complementary imaging diagnostics to personalize treatment and optimize patient outcomes [14].
Stantec Announces Private Offering of $425 Million Senior Unsecured Notes
GlobeNewswire News Room· 2025-05-30 21:15
Core Viewpoint - Stantec Inc. has announced a private placement offering of $425 million in senior unsecured notes with a fixed interest rate of 4.374%, aimed at repaying existing debt and for general corporate purposes [1][2]. Group 1: Offering Details - The offering consists of $425 million aggregate principal amount of senior unsecured notes due June 10, 2032, with a fixed interest rate of 4.374% per annum, payable semi-annually [1][2]. - The notes will be issued at par, resulting in gross proceeds of $425 million, with interest payments commencing on December 10, 2025 [2]. - The notes will rank pari passu with all existing and future senior unsecured indebtedness of Stantec and have been assigned a provisional rating of BBB with a stable trend by DBRS Limited [3]. Group 2: Regulatory and Legal Considerations - The notes will not be qualified for public sale under Canadian securities laws and will be offered on a private placement basis [4]. - The notes have not been registered under the U.S. Securities Act and cannot be offered or sold in the United States or to U.S. persons [4]. Group 3: Company Overview - Stantec is recognized as a global leader in sustainable engineering, architecture, and environmental consulting, addressing significant challenges such as aging infrastructure and energy transition [8][9]. - The company emphasizes the importance of community engagement and diverse perspectives in its projects, aiming to innovate in areas like climate change and digital transformation [10][11].
If There's Such a Thing as a Recession-Resistant Stock, This Is It
The Motley Fool· 2025-05-30 21:15
Company Overview - AutoZone, founded in 1979, has grown from a single store to 6,500 locations in the U.S. and expanding in Mexico and Brazil [4] - The company is recognized for its strong brand and customer service, catering to both automotive repair technicians and DIY customers [3] Financial Performance - For fiscal 2024, AutoZone reported net sales of $18.5 billion, a year-over-year increase of nearly 6%, and earnings per share (EPS) rose 13% to $149.55 [5] - In the third quarter of fiscal 2025, net sales increased by 5.4% to $4.5 billion, with domestic same-store sales up 5% [5] - EPS in the latest quarter decreased by 3.6% compared to the previous year, attributed to aggressive investments in growth rather than weak demand [6] Growth Strategy - AutoZone is focusing on expanding its market share in the commercial sector by enhancing delivery capabilities, increasing sales staff, and opening "mega-hub" stores [7] - The company is committed to long-term growth despite short-term margin pressures due to these investments [7] Market Position - The automotive aftermarket, valued at over $2.3 trillion globally, is characterized by inelastic demand, making AutoZone's core business resilient even during economic downturns [9][10] - The average age of vehicles on U.S. roads has reached a record 12.8 years, indicating a growing need for maintenance and parts, which benefits AutoZone [13] Share Buyback Program - AutoZone has repurchased over $38 billion of its own shares since 1998, significantly reducing its shares outstanding [14][15] - The company has $1.1 billion remaining in its current buyback authorization, indicating a strong commitment to returning value to shareholders [15] Valuation and Future Outlook - AutoZone's forward price-to-earnings ratio is around 25, which is lower than competitor O'Reilly Auto Parts at 31, suggesting reasonable valuation [17] - The U.S. automotive aftermarket is projected to reach $617 billion by 2027, providing substantial growth opportunities for AutoZone [17]
Why Nvidia Stock Dropped to End the Week
The Motley Fool· 2025-05-30 21:13
Core Viewpoint - Nvidia's stock experienced volatility following its strong fiscal Q1 earnings report, with significant concerns regarding the impact of export restrictions to China on future sales [1][3][4]. Financial Performance - Nvidia reported record revenue of $44.1 billion for fiscal Q1, exceeding expectations despite a $4.5 billion charge due to export restrictions on its H20 chip to China [3][4]. - The company anticipates an additional loss of $8 billion in H20 sales for fiscal Q2, indicating ongoing challenges in the Chinese market [4]. Market Dynamics - China accounted for 13% of Nvidia's total revenue last year, highlighting its significance as a market [4]. - CEO Jensen Huang emphasized the closure of the $50 billion China market to U.S. industry, stating that the H20 export ban has severely impacted Nvidia's business in China [6]. Investor Sentiment - Despite the challenges posed by the Chinese market, investor excitement was evident following the earnings report, although concerns about trade tensions led to a decline in stock price [1][5]. - The re-escalation of trade tensions, as indicated by President Trump's comments, contributed to negative sentiment among investors [5][6]. Future Outlook - Nvidia remains optimistic about achieving record quarterly earnings despite the setbacks in China, suggesting potential for future growth [4][7]. - The company is exploring other opportunities beyond the Chinese market, which could lead to further upside in its stock performance [7].
Booking Holdings: Quietly Killing The Competition And Crushing The Market
Seeking Alpha· 2025-05-30 21:05
Group 1 - Booking Holdings has been one of the top performers in the market despite the focus on hot topics like AI, tariffs, inflation, and budget deficits [1] - The company is positioned to attract long-term investors by emphasizing qualitative attributes and fundamental pricing [2] Group 2 - The article aims to provide insights on companies with strong growth potential while managing downside risks [2] - There is a strategy to maintain a concentrated portfolio that avoids underperformers and maximizes exposure to high-performing stocks [2]
Red White & Bloom Brands Provides Update on Status of Annual Filings
GlobeNewswire· 2025-05-30 21:05
TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Red White & Bloom Brands Inc. (CSE: RWB) (“RWB” or the “Company”) is providing an update on the status of a management cease trade order granted on May 1, 2025 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203"). On May 1, 2025, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying managem ...
EnviroGold Announces Appointment of Interim CFO
GlobeNewswire· 2025-05-30 21:05
Company Overview - EnviroGold Global Limited is a clean technology company focused on reprocessing mine waste to produce precious and critical metals while promoting environmental and social sustainability [1][4] - The company operates on a technology licence fee model with low capital expenditure (capex) requirements and aims to establish itself as a leading global technology company focused on shareholder value [4] Management Changes - Mr. Peter Nguyen has been appointed as the Interim Chief Financial Officer, effective immediately [1] - Mr. Nguyen is a Chartered Professional Accountant with over 15 years of experience in finance, financial reporting, regulatory compliance, and public company administration [2] - This appointment follows the resignation of Mr. Kyle Appleby, effective May 20, 2025, and the company expressed gratitude for Mr. Appleby's contributions [3]
Sun Life Announces Dividend Rates on Class A Non-Cumulative Rate Reset Preferred Shares Series 8R and Class A Non-Cumulative Floating Rate Preferred Shares Series 9QR
Prnewswire· 2025-05-30 21:01
TORONTO, May 30, 2025 /PRNewswire/ - Sun Life Financial Inc. (TSX: SLF) (NYSE: SLF) today announced the applicable dividend rates for its Class A Non-Cumulative Rate Reset Preferred Shares Series 8R (the "Series 8R Shares") and Class A Non-Cumulative Floating Rate Preferred Shares Series 9QR (the "Series 9QR Shares").With respect to any Series 8R Shares that remain outstanding after June 30, 2025, commencing as of such date, holders thereof will be entitled to receive non-cumulative preferential cash divide ...
Rosen Law Firm Encourages Semler Scientific, Inc. Investors to Inquire About Securities Class Action Investigation - SMLR
Prnewswire· 2025-05-30 21:00
NEW YORK, May 30, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Semler Scientific, Inc. (NASDAQ: SMLR) resulting from allegations that Semler Scientific may have issued materially misleading business information to the investing public.So What: If you purchased Semler Scientific securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conting ...
NFI Announces Pricing of $600 million Second Lien Notes Offering
GlobeNewswire· 2025-05-30 21:00
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES WINNIPEG, Manitoba, May 30, 2025 (GLOBE NEWSWIRE) -- (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (“NFI” or the “Company”), a leader in propulsion agnostic bus and coach mobility solutions, today announced that its subsidiary, New Flyer Holdings, Inc. (the “Issuer”), has entered into a binding purchase agreement with a syndicate of initial purchasers and priced its previously announced private offering of senior secu ...